Goldman Sachs

A Goldman Sachs analyst said that Myriad's third share repurchase program in less than 12 months "is reflective of slowing organic growth and increasing dependence on financial engineering to drive bottom-line growth."

In addition to initiating coverage of Cepheid, Gen-Probe, Myriad Genetics, and Qiagen, the investment bank also began coverage of Alere and Hologic.

Despite the drop in mass-spec sales, CEO Greg Lucier said "It was a very good quarter for our mass-spec business." Companywide revenues inched up 1 percent to $785M on a pro forma basis.

The change removes "drag from the revenue" but could also fuel speculation that Life Tech is considering divesting the unit. Officials reiterated the firm’s intent to "run the business for success."

News Scan


MDS, Cenix BioScience, Boehringer Ingelheim, Life Technologies, Molecular Devices


Researchers in China have generated mouse pups from same-sex parents, according to Scientific American.

Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.

The South China Morning Post reports that Hong Kong plans to add HK$20 billion (US$2.6 billion) to a research endowment.

In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.